IP Library › Granted Patent US 7,078,195
Granted Patent B2
US 7,078,195 · App. 10/713,881 · Granted Jul 18, 2006

Antibiotics AA-896

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,078,195
App. No.
10/713,881
Granted
Jul 18, 2006
Kind
B2
Abstract

This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-Bl, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-896-D1, AA-896-D2, AA-896-D3 and AA-896-D4 derived from the microorganism Streptomyces spp. LL-AA896 which are useful an anti-bacterial agents.

Claims (53)

1. A process for producing a antibiotic AA-896 compound of the formula

wherein:

or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of Streptomyces spp. selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

2. A process for producing a antibiotic AA-896 compound of the formula

wherein:

or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of Streptomyces spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

3. A process for producing a antibiotic AA-896 compound of the formula

wherein:

or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of Streptomyces spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892 or an antibiotic AA-896 producing mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

4. A process for producing a antibiotic AA-896 compound of the formula

or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of Streptomyces spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

5. A process for producing a antibiotic AA-896 compound of the formula

or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of Streptomyces spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

6. An isolated microorganism Streptomyces spp. LL-AA896, strain LL4774 or an AA-896 antibiotic producing mutant thereof.

7. The isolated microorganism of claim 6 wherein the AA-896 antibiotic producing mutant is strain LL4794, prepared by mutagenesis of strain LL4774.

8. The isolated microorganism of claim 6 wherein the AA-896 antibiotic producing mutant is strain LL4802, prepared by mutagenesis of strain LL4774.

9. The isolated microorganism of claim 6 wherein the AA-896 antibiotic producing mutant is strain LL4808, prepared by mutagenesis of strain LL4774.

10. The isolated microorganism of claim 6 wherein the AA-896 antibiotic producing mutant is strain LL469, prepared by mutagenesis of strain LL4774.

11. The isolated microorganism of claim 6 wherein the AA-896 antibiotic producing mutant is strain LL479, prepared by mutagenesis of strain LL4774.

12. The isolated microorganism of claim 6 wherein the AA-896 antibiotic producing mutant is strain LL482, prepared by mutagenesis of strain LL4774.

13. A process for producing a antibiotic AA-896 compound of the formula

or pharmaceutically acceptable salts thereof

wherein:

said process comprising:

cultivating a producing strain of Streptomyces spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL479 and LL482 or an antibiotic AA-896 producing mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

14. A process for producing a antibiotic AA-896 compound of the formula

wherein:

R 1 is H or

R 2 is H, OH or OCH 3 ;

R 3 is H or CH3;

R 4 is represented by the formula

n is an integer from 4 to 12;

R 5 is straight and branched alkyl of 1 to 4 carbon atoms, carbamimidoylamino or carbamimidoylhydroxyamino;

or a pharmaceutically acceptable salt thereof

said process comprising:

cultivating a producing strain of Streptomyces spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL479, LL469 and LL482 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

15. The process according to claim 14 , wherein the producing strain is selected from the group LL4774, LL4794, LL4802, LL4808, LL479, and LL482.

16. The process according to claim 1 wherein the producing strain of Streptomyces spp. is selected from the group LL4774, LL4794, LL4802, LL4808 and LL482.

17. The process according to claim 2 wherein the producing strain of Streptomyces spp. is selected from the group LL4774, LL4794, LL4802, LL4808, LL469 and LL482.

18. The process according to claim 3 wherein the producing strain of Streptomyces spp. is selected from the group LL4774, LL4794, LL4802, LL4808, LL469, LL479 and LL482.

19. The process according to claim 4 wherein the producing strain of Streptomyces spp. is selected from the group LL4774, LL4794, LL4802, LL4808, LL469, and LL482.

20. The process according to claim 5 wherein the producing strain of Streptomyces spp. is selected from the group LL4774, LL4794, LL4802, LL4808, LL469, LL479 and LL482.

21. The process according to claim 13 wherein the producing strain of Streptomyces spp. is selected from the group LL4774, LL4794, LL4802, LL4808, LL479 and LL482.